Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com - TD Cowen has reiterated its Buy rating and $25.00 price target on Dynavax Technologies (NASDAQ:DVAX), currently trading at $11.12, following the company’s announcement of positive topline data for its candidate shingles vaccine. With analyst targets ranging from $11 to $32, InvestingPro data shows the stock currently trading near its Fair Value.
The company reported that its Z-1018 vaccine demonstrated comparable immunogenicity to the active comparator Shingrix, including similar antibody and T cell responses, while showing lower post-injection adverse events.
Dynavax plans to present the full data set, which will include additional doses and regimens, at an upcoming medical meeting, according to TD Cowen’s analysis.
The biotechnology company will advance development of the 100 mcg + alum formulation with an 8-week interval dosing schedule into Part 2 of its clinical program, which will focus on subjects aged 70 and older in the second half of 2025.
TD Cowen’s maintained Buy rating reflects its positive outlook on Dynavax’s shingles vaccine program, which appears to be showing competitive efficacy with a potentially improved safety profile compared to the current market leader.
In other recent news, Dynavax Technologies Corporation reported its second-quarter 2025 earnings, surpassing analysts’ expectations. The company achieved an earnings per share of $0.14, exceeding the forecasted $0.10, while revenue reached $95.44 million, above the anticipated $85.57 million. Additionally, Dynavax announced positive topline results from its Phase 1/2 clinical trial for its shingles vaccine candidate, Z-1018. The trial indicated that Z-1018 demonstrated comparable immune responses to GlaxoSmithKline (NYSE:GSK)’s Shingrix and showed a significantly better tolerability profile. At the selected dose formulation, Z-1018 achieved a 100% humoral vaccine response rate compared to 96.9% for Shingrix. Despite these developments, Goldman Sachs reiterated its Sell rating on Dynavax stock, maintaining a price target of $11.00. The firm acknowledged the positive trial data but did not adjust its rating. These recent developments highlight the ongoing progress and challenges faced by Dynavax in the pharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.